{"entity":{"id":"nct07071961","kind":"trial","name":"Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Di","aka":[],"tldr":"A phase 2 trial of regorafenib and lorigerlimab in colorectal cancer, run by M.D. Anderson Cancer Center, now recruiting.","summary":"Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial] is a phase 2, interventional study registered as NCT07071961 by M.D. Anderson Cancer Center, with a registry enrolment figure of 16 participants, started 2026-02-11 and due to reach its primary completion in 2027-05-01. Interventions recorded: Regorafenib (CT); Lorigerlimab. Conditions listed: Colorectal Cancer; Regorafenib; High Risk Patients. Primary outcome: Safety and adverse events (AEs). Colorectal eligibility wording from the registry: \"* History of hysterectomy or bilateral salpingo-oophorectomy\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07071961","url":"https://clinicaltrials.gov/study/NCT07071961"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors","mrd-testing"],"targets":[],"drugs":["regorafenib","lorigerlimab"],"companies":["bayer","macrogenics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07071961","phase":"2","setting":"Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]","sponsor":"M.D. Anderson Cancer Center","enrolled":16,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07071961/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"lorigerlimab","kind":"drug","name":"Lorigerlimab","route":"/drugs/lorigerlimab/"},{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/"}],"company":[{"id":"bayer","kind":"company","name":"Bayer","route":"/companies/bayer/"},{"id":"macrogenics","kind":"company","name":"MacroGenics","route":"/companies/macrogenics/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}